MedTrace Logo

Plasma Proteomic Biomarkers for Early Diagnosis of Lung Cancer

NCT05742204 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 3700

Last updated 2025-05-15

No results posted yet for this study

Summary

We will identify plasma proteomics biomarkers for early diagnosis of lung cancer.

Conditions

Interventions

OTHER

Plasma protein biomarker analysis

Plasma samples from lung cancer patients were collected at the time of their diagnosis, prior to the initiation of treatment.We will use TMT-based proteomics approaches to analyze more than 2000 proteins in plasma samples from lung cancer patients .

OTHER

Plasma protein biomarker analysis

Plasma samples of control subjects were collected.

Sponsors & Collaborators

  • Second Affiliated Hospital, School of Medicine, Zhejiang University

    lead OTHER

Principal Investigators

  • Weilin Wang · 2nd Affiliated Hospital, School of Medicine, Zhejiang University

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-02-01
Primary Completion
2025-05-01
Completion
2032-10-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05742204 on ClinicalTrials.gov